1

The Rise and Fall (History & Context)

What the Company Did at Its Peak

Scorpius is the latest incarnation of a long-running small-cap biotech platform that started life as an immuno-oncology company and pivoted into biologics contract development and manufacturing (CDMO).

The current business (continuing ops) is a CDMO focused on process development, cGMP manufacturing and analytical services for biologics and advanced therapies from its San Antonio facility.

FY 2024 Revenue
$6.24M
Net Loss
$(34.3)M
Operating Cash Burn
$(26.0)M
⚠️
Severely Under-Utilized Platform

As of FY 2024, the CDMO generated only $6.24M in revenue but posted a net loss of $34.3M and operating cash burn of $26.0M, highlighting a severely under-utilized, cost-heavy platform.

Timeline of the Downfall – Key Pivot Points

2019–2022
Big CAPEX & Strategic Pivot

The legacy company invested heavily in CDMO infrastructure and long-term leases, taking on major lease liabilities for the San Antonio facility and related equipment.

The strategy depended on filling a large, expensive facility with external biologics clients—a high-operating-leverage business model.

2023–2024
Under-utilization + Heavy Losses

CDMO revenue stalled at ~$7.0M (2023) → $6.24M (2024) while net losses remained massive: $(46.8)M in 2023 → $(34.3)M in 2024.

Net cash used in operating activities was $26.0M in 2024 despite only ~$6M of revenue.

As of Dec 31, 2024, Scorpius had $39.2M in total assets vs. $37.5M in total liabilities, including $16.0M of current "convertible promissory notes payable, related party", and lease liabilities of ~$12.5M.

Dec 2024
Highly Structured Secured Financing

In December 2024, Scorpius issued Senior Secured Convertible Notes with aggregate original principal of $13.39M, plus a "Make-Whole Amount" of $3.615M and restrictive covenants (including net monthly cash burn limits).

These notes are senior secured against substantially all assets and quickly became the core of the capital structure.

Early 2025
Going-Concern, Repeated Listing Deficiencies & Delisting

The 2024 10-K (filed Apr 30, 2025) disclosed:

  • Cash + short-term investments only $1.2M at 12/31/24, and $2.1M at April 30, 2025 (after a first-tranche private placement).
  • Management's estimate that existing resources would fund operations only through April 2025.
  • An accumulated deficit of ~$287.2M and explicit "substantial doubt" about ability to continue as a going concern.

The company received multiple NYSE American deficiency notices for late filings in 2024 and again on Apr 16, 2025 for failure to timely file the 2024 annual report and March 2025 10-Q.

On Apr 21, 2025, NYSE Regulation moved toward delisting, and on May 2, 2025, a Form 25-NSE ("Forced Delisting") was filed. After that, SCPX stopped trading on NYSE American and shifted to the OTC market as a distressed micro-cap.

Feb–Aug 2025
Strategic Alternatives & Serial Lifeline Financings

On Feb 25, 2025, Scorpius announced it had engaged A.G.P./Alliance Global Partners to "explore strategic alternatives", including sale, merger or asset transactions.

Throughout 2025, it entered into a series of promissory notes, amendments, and debt-equity swaps to stay alive:

  • Promissory notes in Jan, Feb, Apr, Jun, Jul 2025, and amendments to the December 2024 Senior Secured Notes.
  • Multiple debt-equity swaps and equity offerings (May–July 2025), and lease terminations / assignments, signalling severe stress in both capital structure and operations.
Sept–Oct 2025
Default & Foreclosure Process Initiated

Sept 15, 2025: 8-K (summarized by StockInsights as "Loan Default Notice") – the company disclosed defaults under its secured notes.

Oct 8, 2025: 8-K – Scorpius entered a $500,083 loan and secured up to $5M in additional funding under a new financing arrangement—another short-term patch.

Oct 10, 2025: The critical inflection point:

  • Scorpius received a "Notice of Public Disposition" under the UCC from the collateral agent for the Senior Secured Convertible Notes and other secured notes.
  • These Secured Notes (convertible and non-convertible) represented obligations in excess of $26.05M at the time.
  • The collateral agent stated it would sell all or part of the collateral—which includes all personal property and assets of the company and its subsidiaries, notably Scorpius BioManufacturing (94% owned) and Skunkworx Bio (100% owned)—at a public auction on Nov 12, 2025.
Nov 2025
Last-ditch Micro-Financings & Late Q3 Filing

Nov 17, 2025 8-K: Scorpius disclosed four non-convertible promissory notes to a single institutional investor:

  • Principal amounts: $471k (Oct 14), $441k (Oct 27), $101,176 (Nov 3), $345k (Nov 10); total ~$1.36M.
  • Each note bears 5% interest, a 15% premium payable on repayment, and allows the holder to demand repayment with up to 100% of proceeds of any subsequent financing.

Nov 18, 2025: Scorpius filed an NT 10-Q (Form 12b-25) announcing it cannot timely file its Q3 2025 10-Q, continuing its pattern of late SEC reporting.

Nov 25, 2025 8-K (last 7 days): The company issued yet another non-convertible promissory note for $122,000 to the same investor, also at 5% interest + 15% premium, with similar redemption features.

Press Releases (Last 7 Days)

📰

Scorpius's IR "Press Releases" page shows no new company press releases in 2025; the latest are from 2024.

Recent news coverage (e.g., MarketScreener, Investing.com) is essentially machine-generated summaries of the SEC filings, not fresh strategic announcements.

Bottom line: the "rise" was the CDMO build-out; the "fall" has been a multi-year burn-through of capital culminating in secured creditors moving to foreclose on essentially all operating assets.
2

Current Condition & Vital Signs

As of November 27, 2025

Liquidity & Cash Burn

From the FY 2024 10-K (filed Apr 30, 2025):

Cash & Short-term Investments

Cash at Dec 31, 2024
$1.2M
Cash at Apr 30, 2025
$2.1M
After early-2025 financing

Operating Cash Burn

  • Net cash used in operating activities in 2024 was $26.0M, down from $31.5M in 2023.
  • Roughly, the company consumed >$2M/month in cash to support a business generating only ~$6M in annual revenue.

Management explicitly stated its cash resources would fund operations only through April 2025, absent additional capital, and raised "substantial doubt" about the company's ability to continue as a going concern.

Recent Financing Activity

Since then, Scorpius has added multiple small promissory notes:

  • At least $1.36M (Oct–Nov 10, 2025) and another $122k on Nov 10–Nov 25, 2025 via the recent 8-Ks.
  • Earlier in 2025, numerous other notes and swaps (Feb–July) added several million more of short-term obligations.
💸
Critical Liquidity Situation

Given the historical burn rate and the modest magnitude of these emergency financings, liquidity is still critically thin. The company appears to be funding operations week-to-week via very expensive bridge debt, under the shadow of a UCC foreclosure.

Debt Load & Capital Structure

Secured Notes

  • Senior Secured Convertible Notes (Dec 2024) + a Sept 30, 2025 non-convertible note ($500,083) + other promissory notes.
  • As of Oct 10, 2025, total obligations under these Secured Notes exceeded $26.0M, prompting the collateral agent to initiate UCC foreclosure proceedings over all personal property and assets, including CDMO and Skunkworx equity.

Balance Sheet at 12/31/24

Item Amount
Total Assets $39.2M
Total Liabilities $37.5M
Convertible Promissory Notes (current) $16.0M
Lease Liabilities (current + long-term) $12.5M

New 2025 Notes (Unsecured or "junior-ish" bridge)

The four Oct–Nov 2025 notes (~$1.36M) and the Nov 10/25, 2025 note ($122k) bear 5% interest plus a 15% premium and contain "use up to 100% of financing proceeds to repay us" clauses—classic distressed bridge terms.

In economic reality, secured lenders control the fulcrum: with >$26M in secured obligations versus assets that are likely worth materially less than book, common equity is deeply out-of-the-money.

Listing / Trading Status

  • Scorpius's common stock was delisted from NYSE American following deficiency notices and a Form 25-NSE filed May 2, 2025 (labeled "Forced Delisting" by secondary data sources).
  • The shares now trade on the OTC market under ticker SCPX, at penny-stock levels with micro-cap market capitalization (orders of magnitude smaller than the $26M+ secured debt stack).

Chapter 11 Status

📋

No Chapter 11 (or Chapter 7) filing appears in recent SEC filings or news as of Nov 27, 2025. Searches for "Scorpius Holdings Chapter 11/bankruptcy" return only references to the UCC foreclosure process, not a formal court filing.

Instead, creditors are currently pursuing out-of-court foreclosure via UCC sale of substantially all assets.

"Most Recent" 8-K / Press Releases (Last 7 Days)

  • Most recent 8-K (Nov 25, 2025): another $122k non-convertible note with 5% interest + 15% premium to the same institutional investor; signals that the company is still scrambling for cash and has not resolved its capital structure.
  • Press releases: None from the company itself in 2025; external news in the last week is just repackaged SEC filings, not evidence of new strategic deals or rescues.
3

The Autopsy – Why It Went South

External Factors

1. Biotech / Funding Downcycle & Crowded CDMO Market

The period 2022–2025 has seen a sharp slowdown in early-stage biotech funding, higher capital costs, and increased selectivity by sponsors, which has pushed pricing pressure and under-utilization risk onto smaller CDMOs.

Large, well-capitalized CDMOs dominate key relationships; for a small new entrant with a single facility, filling capacity quickly enough to cover fixed costs is extremely difficult.

2. High-rate Environment & Tight Capital Markets

The company's financing structures (secured convertibles with make-wholes and short-term promissory notes with double-digit effective yields and 15% premiums) are symptomatic of very tight capital access in a high-interest-rate regime.

Internal Factors (Execution & Capital Structure)

1. Under-utilized, Capital-Intensive Business Model

In 2024, Scorpius produced $6.24M of revenue vs. a $34.3M net loss and $26.0M of operating cash burn, a loss/cash-burn multiple of ~4–5x revenue.

Lease-driven fixed costs remained high: operating + finance lease liabilities at $12.5M, with right-of-use assets of $22.0M.

🏭
Put simply, the facility never achieved economic scale—it was a large, expensive factory being fed by a thin pipeline of projects.

2. Fragile Revenue Model

The 10-K emphasizes that Scorpius generally does not have long-term contracts; customers can reduce, reschedule or cancel CDMO work with limited notice.

That makes future revenue highly uncertain, amplifying the risk of mismatch between fixed costs and volatile orders.

3. Aggressive and Opaque Financing Structures

The December 2024 Senior Secured Convertible Notes came with:

  • High effective yields (cash interest plus "Make-Whole" of $3.615M).
  • Tight burn-rate covenants and strong collateral rights.

The company repeatedly amended and layered on additional promissory notes throughout 2025, including multiple high-fee, high-premium loans in 2025.

This left Scorpius with a complex, top-heavy capital structure where secured creditors effectively owned the downside and upside, while common equity was massively subordinated.

4. Chronic Reporting & Control Issues

Repeated late filings (2023 10-K, 2024 Q1, 2024 10-K, 2025 Q3) led to multiple NYSE American non-compliance notices, ultimately ending in delisting.

The 2024 10-K reports that disclosure controls and internal control over financial reporting were not effective due to material weaknesses.

5. Lethal Blows

  • (a) Forced Delisting (Apr–May 2025) The loss of a national exchange listing removed a key equity-capital lifeline and sharply reduced institutional investor interest and liquidity.
  • (b) Default on Senior Secured Notes & UCC Foreclosure Notice (Oct 10, 2025) The UCC "Notice of Public Disposition" acknowledging defaults and a plan to sell all assets securing $26M+ of debt is the effective "point of no return" for common equity.
  • (c) Loss of "Normal" Financing Tools The 10-K notes the company cannot currently use a Form S-3 shelf until at least April 2026 because of late filings, limiting its access to at-the-market and other efficient equity offerings.
Net result: the business never earned its cost of capital, and when cash markets tightened, the highly levered, covenant-heavy capital structure quickly pushed the company into creditors' hands.
4

Forensic Analysis – Early Warning Signs

12–24 Months Before Foreclosure

Quantitative Red Flags

Using FY 2024 data (available April 30, 2025):

1. Negative Working Capital & High Leverage

  • Current assets (24.2M) < current liabilities (26.3M) at Dec 31, 2024—current ratio <1.0.
  • Total liabilities (37.5M) almost equal total assets (39.2M) → very thin equity buffer.

2. Extremely Weak Profitability & Cash Flow

  • Net loss: $(34.3)M on $6.24M revenue → losses ~5.5× revenue.
  • Net cash used in operating activities: $26.0M.
  • For any Altman-style distress model, these numbers would produce a deep "distress-zone" Z-score (<1.23): negative retained earnings, heavy leverage, and persistent operating losses.

3. Deteriorating Capital Structure

  • Rapid build-up of convertible promissory notes and senior secured debt, including $13.39M of Senior Secured Convertible Notes in Dec 2024 plus $16M of current convertible note liabilities on the 12/31/24 balance sheet.
  • 2024 cash flows show $25.6M net cash provided by financing activities, mostly from issuances of equity and debt—i.e., the company is living entirely off capital raises rather than operations.

4. Altman-Style Interpretation

While we don't compute the exact Z-Score here, the combination of:

  • Negative working capital.
  • Very high leverage (liabilities ≈ assets).
  • Sustained losses and cash burn.
  • Tiny market capitalization vs. liabilities.

would flag Scorpius as deeply distressed at least 12–18 months before the UCC foreclosure notice.

Qualitative Red Flags

1. Going-Concern Language

The 2024 10-K explicitly states "substantial doubt about the Company's ability to continue as a going concern within one year", with cash projected to last only through April 2025 without new capital.

2. Exchange Non-Compliance & Delisting Threats

Multiple NYSE American deficiency notices in 2024 and 2025 for late SEC filings, culminating in the April 21, 2025 delisting notice and May 2, 2025 Form 25 filing.

3. Serial "Rescue" Financings & Amendments

The dense sequence of promissory notes, note amendments, debt-equity swaps and equity offerings across 2024–2025 is a classic pattern of a company stuck in permanent rescue mode rather than orderly long-term capital planning.

4. Strategic Alternatives Announcement (Feb 2025)

Engaging A.G.P. to explore "strategic alternatives" (sale, merger, asset sale) is a loud distress signal, especially when no positive outcome materializes over the subsequent 9+ months.

5. Control & Reporting Weaknesses

Material weaknesses in internal controls and repeated tardy filings indicate organizational strain and inadequate finance infrastructure, impairing stakeholder confidence.

🚨
Warning Signs Summary

Taken together, the warning signs were abundant by early 2024, and glaring by the April 2025 10-K.

5

Turnaround Probability Assessment

5.1 Restructuring vs. Liquidation / Foreclosure

Key Economic Reality

  • Secured Notes obligations >$26.0M at Oct 10, 2025.
  • Book assets ~ $39.2M at Dec 31, 2024, but this includes specialized CDMO equipment and right-of-use assets—unlikely to realize book value in a distressed sale.
  • Additional layers: lease liabilities, trade creditors, smaller promissory notes, and other obligations.

Foreclosure Trajectory

  • The UCC Notice contemplates public sale of substantially all assets, including equity interests in the operating subsidiaries.
  • If that sale closes and secured creditors credit-bid their debt, the public company could be left as a near-asset-less shell with legacy liabilities and NOLs but minimal operating business.

Restructuring Options (in theory)

  1. Out-of-court recap with secured lenders

    Senior creditors convert part of their claims into new equity in the operating business, possibly wiping out or massively diluting existing common. This could retain operations under a new cap table, but existing equity would only survive as a tiny sliver at best.

  2. Chapter 11 reorganization

    Secured lenders could drive a pre-packaged plan, again resulting in equity cancellation or near-total dilution.

  3. Asset sale to strategic buyer

    A strategic buyer might pay enough to satisfy a portion of secured debt, but there is no evidence of a binding deal despite months of "strategic alternatives" work.

Probability Assessment (Subjective, Based on Public Info)

80–90%
Liquidation / Creditor-Controlled Foreclosure
High probability that the outcome is effectively a liquidation or creditor-controlled foreclosure, whether or not a formal Chapter 7 is filed.
10–20%
Restructuring Preserves Going-Concern
Low probability that a restructuring preserves a going-concern operating entity under current corporate umbrella—and existing common shareholders would almost certainly be massively diluted.
<5%
Common Retains Meaningful Value
Probability that existing common retains meaningful economic value (>10% of pro-forma equity) is very low (single-digit percentage at best).

5.2 Is There Any Value Left for Common Equity?

Given:

  • Secured obligations >26M vs. likely lower realizable asset value.
  • Additional layers of liabilities and ongoing cash burn.
  • Loss of listing and dependence on expensive micro-loans.
📉
Common Equity is Economically Out-of-the-Money

Any "value" in SCPX common is essentially a long-dated option on a highly unlikely over-recovery scenario where:

  • CDMO assets sell for well above distressed expectations, and
  • Secured creditors agree to leave some residual stake for current shareholders rather than taking everything through credit bids and new equity, and
  • No further large claims emerge (litigation, lease damage claims, etc.).

That is a very thin, speculative path.

6

Risk Profile for Speculators

"Catching the Falling Knife"

For anyone contemplating SCPX as a distressed trade, the risk profile is extreme:

6.1 Market & Trading Risks

Liquidity

Post-delisting, the stock trades on the OTC, with low volumes and wide bid-ask spreads typical of micro-cap distressed names.

Volatility

Price can move dozens of percentage points intraday on tiny volumes.

News flow (any update on the UCC sale, 10-Q filing, or new financing) could trigger violent spikes or collapses.

Execution Risk

  • Large orders can move the market against you.
  • Some brokers restrict trading in Expert Market / high-risk OTC names, increasing the risk of being unable to exit during stress.

6.2 Fundamental & Event Risks

  • 1. Foreclosure / Asset-Sale Outcome If the creditor-run UCC sale closes and secured lenders take the assets, the listed entity could be left a shell; equity could trade purely on retail speculation or be effectively worthless.
  • 2. Potential Future Bankruptcy Filing Even after asset disposition, the company might still file Chapter 11 or 7 to deal with residual liabilities, in which case common equity is almost always cancelled.
  • 3. Ongoing Dilution Any "rescue" equity financing (if somehow arranged) would likely be massively dilutive at current price levels, further eroding existing holders.
  • 4. Reporting & Information Risk The company is late on its Q3 10-Q, and historically has struggled with timely reporting and internal controls. Investors are effectively trading on stale financials, while the true balance sheet and P&L are likely worse than the last audited snapshot.
  • 5. Legal / Regulatory Overhang Delisting, defaults, and control weaknesses all raise the probability of shareholder litigation, creditor lawsuits, or regulatory scrutiny, any of which could impose additional costs or constraints.

Practical Takeaways for a Distressed/Forensic Lens

Perspective Assessment
From a creditor's perspective The Senior Secured Noteholders clearly control the situation; they have collateral over all assets and are already pursuing foreclosure. Their recovery is uncertain but materially ahead of equity.
From an equity speculator's perspective SCPX is not a classic "deep value" situation; it is closer to a binary lotto ticket on improbable over-recovery or an unexpected white-knight deal. The expected value of common equity, based purely on capital-structure math, is close to zero, with a very fat-tailed distribution (occasional spikes, but a high probability of permanent loss).